Humanigen (HGEN) Announces Resignations of Three Directors, Company Now not Compliant with Nasdaq Rules

On July 18, 2023, John Hohneker resigned from the Board of Humanigen Inc. (NASDAQ: HGEN), and on July 19, 2023 Cheryl Buxton and Kevin Xie both resigned from the Board, in each case with immediate effect. The decisions
of Dr. Hohneker, Ms. Buxton and Mr. Xie to resign were not the result of disagreements with Humanigen on any matter relating to Humanigen's operations, policies or practices.

As a result of the reported resignations of three members of the board of directors (the “Board”) of Humanigen, Inc. (the “Company”), the Company notified The Nasdaq Stock Market of the Company’s non-compliance with each of Nasdaq Rule 5605(b)(1), which requires a Nasdaq-listed company to have a board of directors comprised of a majority of independent directors; and Nasdaq Rule 5605(c)(2), which requires a Nasdaq-listed company to have an audit committee of the board of directors comprised of at least three independent directors meeting the eligibility
requirements of that Rule.

You May Also Be Interested In

• Boeing names Ryan Shedd as new SVP and controller
• Alzamend Neuro (ALZN) files for 98.4M share offering by selling stockholders
• Yum! Brands adds former HanesBrands CEO to its board